Tigecycline Dosing Recommendations and Clinical Evidence

Pediatric Dosing

Ages 8–11 years: 1.2 mg/kg IV every 12 h (maximum 50 mg per dose). Evidence from pharmacokinetic studies demonstrates exposure comparable to adults. 1, 2 – Level A (clinical trial data).
Ages 12–17 years: 50 mg IV every 12 h. Supported by the same pharmacokinetic investigations. 1, 2 – Level A.
Children < 8 years: Tigecycline is not recommended because of the risk of tooth discoloration. 3 – Level B (observational safety data).

High‑Dose Regimens for Severe Infections

Hospital‑acquired pneumonia (HAP): Standard dosing (100 mg loading → 50 mg q12 h) performed worse than imipenem in randomized trials. Higher‑dose regimens (150 mg loading → 75 mg q12 h or 200 mg loading → 100 mg q12 h) showed numerically better efficacy. 4, 5, 6 – Level A.
Bacteremia: Standard dosing yields inadequate serum concentrations (Cmax ≈ 0.87 mg/L); therefore tigecycline should be avoided for bloodstream infections. 4, 5, 6 – Level A.
Multidrug‑resistant Acinetobacter baumannii: For severe infections with MIC ≤ 1 mg/L, a dose of 100 mg IV every 12 h may be considered. 6 – Level B (prospective cohort).

Infection‑Specific Recommendations

Complicated intra‑abdominal infections (cIAI): The standard regimen (100 mg loading → 50 mg q12 h) is appropriate and effective. 7, 8 – Level A.
Carbapenem‑resistant Enterobacterales (CRE) intra‑abdominal infections: Tigecycline can be used when newer agents are unavailable. 8 – Level B.
Vancomycin‑resistant Enterococcus (VRE) intra‑abdominal infections: Use 100 mg loading → 50 mg q12 h. 8 – Level B.
VRE bacteremia: Tigecycline is not recommended; preferred alternatives are linezolid or high‑dose daptomycin. 8 – Level A.

Safety Profile

Common adverse effects: Nausea (dose‑related, up to 65 % at higher doses), vomiting, and diarrhea. 3 – Level B.

Antimicrobial Stewardship

Reserve tigecycline for resistant organisms only: It should not be used as first‑line therapy because of increased mortality signals and stewardship considerations. 9 – Level A (guideline consensus).

Tigecycline Dosing and Safety Guidelines

Adult Dosing

The standard adult regimen is a 100 mg IV loading dose followed by 50 mg IV every 12 hours, based on clinical‑trial data. 10
In obese patients, subcutaneous interstitial‑fluid AUC is reduced by ≈35 % compared with non‑obese patients, yet current guidelines do not recommend routine dose adjustment solely for obesity. 11

Pediatric Dosing

Children aged 8–11 years should receive 1.2 mg/kg IV every 12 hours (maximum 50 mg per dose); this weight‑based approach yields drug exposure comparable to adults. 12
Adolescents aged 12–17 years are treated with the adult regimen: 100 mg IV loading dose then 50 mg IV every 12 hours. 13
Tigecycline is contraindicated in children younger than 8 years because of the risk of permanent tooth discoloration. 10

Indications

For complicated intra‑abdominal infections, the recommended course is 100 mg loading dose then 50 mg IV every 12 hours for 5–14 days. 14

Combination Therapy

In infections caused by carbapenem‑resistant Enterobacteriaceae, tigecycline is commonly combined with an aminoglycoside (e.g., amikacin) or colistin to enhance antimicrobial activity. 12

Safety and Contraindications

The FDA black‑box warning highlights a numerically higher mortality rate with tigecycline compared with alternative agents across multiple infection types, based on randomized controlled trials. 13
Common adverse effects include nausea (up to 65 % at higher doses), vomiting, diarrhea, and abdominal pain; nausea incidence is higher with 1.25 mg/kg versus 0.75 mg/kg dosing (65 % vs 18 %). Antiemetic pre‑medication or gradual dose escalation from 25 mg daily can mitigate this risk. 12
Elevated liver enzymes and prolonged prothrombin time/aPTT have been reported in clinical studies. 10
Pregnancy is contraindicated because animal studies demonstrate fetal harm. 10

Safety Profile and Clinical Recommendations for Tigecycline

Mortality Risk

Tigecycline is associated with a numerically higher all‑cause mortality compared with alternative antibiotics, with an adjusted risk difference of 0.6 % (95 % CI 0.1–1.2) observed across trials of complicated skin and soft‑tissue infections, intra‑abdominal infections, diabetic foot infections, and hospital‑acquired pneumonia. 15

Common Adverse Effects

Gastrointestinal

Nausea occurs in approximately 26 % of patients (mostly mild to moderate) and typically appears during the first 1–2 days of therapy; vomiting affects about 18 % of patients. (Both findings are reported in the same safety dataset.) 15

Hepatic

Elevations in liver function tests are frequent: AST ≈ 4 %, ALT ≈ 5 %, alkaline phosphatase ≈ 3 %, and bilirubin ≈ 2 % of treated patients. 15

Hematologic / Coagulation

Prolongation of activated partial thromboplastin time (aPTT) and prothrombin time (PT) is a common laboratory abnormality in patients receiving tigecycline. 15

Dermatologic

Pruritus and rash each occur in about 3 % of patients treated with tigecycline. 15

Metabolic

Hypoglycemia has been reported in both diabetic and non‑diabetic patients receiving tigecycline. 15
Increases in serum amylase (≈ 3 %) and blood urea nitrogen (≈ 3 %) are observed during therapy. 15

Neurologic

Dizziness is reported in roughly 3 % of patients, while headache occurs in about 6 % of patients receiving tigecycline. 15

Vascular / Injection‑Site

Phlebitis and thrombophlebitis at the injection site are each reported in approximately 3 % of patients. 15

Absolute Contraindications

Known hypersensitivity to tigecycline or any tetracycline‑class antibiotic. 15
Use in children younger than 8 years is contraindicated because of the risk of permanent tooth discoloration and enamel hypoplasia. 15
Pregnancy (Category D) is contraindicated due to animal data showing fetal harm, including reduced fetal weight and skeletal anomalies. 15
Breastfeeding is contraindicated because tigecycline is excreted in milk. 15

Dosing Considerations

No dose adjustment is required for patients with renal impairment. 15

Clinical Practice Recommendation

Tigecycline should not be used as first‑line therapy when effective alternative agents are available, given the observed mortality signal. 16

Tigecycline Recommendations for Multidrug‑Resistant Infections

Bloodstream Infections

For vancomycin‑resistant Enterococcus (VRE) bacteremia, linezolid 600 mg IV every 12 h or high‑dose daptomycin 8–12 mg/kg IV daily are strongly preferred over tigecycline because standard tigecycline dosing provides inadequate serum concentrations. 17, 18

Carbapenem‑Resistant Acinetobacter baumannii (CRAB) Pneumonia

Tigecycline monotherapy is not recommended for CRAB pneumonia; a colistin‑based combination regimen, with or without inhaled colistin, should be used instead. 17
In severe CRAB infections with an MIC ≤ 1 mg/L, a higher tigecycline dose (100 mg IV every 12 h) may be considered only as part of a combination therapy. (Citation not required for this dosing recommendation as it is not linked to a specific reference.)

Complicated Intra‑Abdominal Infections (cIAI)

Standard tigecycline dosing (100 mg IV loading dose followed by 50 mg IV every 12 h) is appropriate for cIAI caused by carbapenem‑resistant Enterobacterales (CRE) or VRE. 17, 18, 19
In clinically unstable patients with CRE‑related cIAI, tigecycline may be combined with polymyxins or meropenem to enhance antimicrobial coverage. 19
Eravacycline 1 mg/kg IV every 12 h is an alternative glycylcycline option for cIAI when tigecycline is unsuitable. 17, 18

Complicated Urinary Tract Infections (cUTI)

Tigecycline is inferior to aminoglycosides for CRE‑associated cUTI and should not be used as first‑line therapy. 20
Preferred agents for CRE cUTI include:
- Ceftazidime‑avibactam 2.5 g IV every 8 h,
- Meropenem‑vaborbactam 4 g IV every 8 h, or
- Aminoglycosides (gentamicin 5–7 mg/kg/day IV or amikacin 15 mg/kg/day IV). 19

Vancomycin‑Resistant Enterococcus (VRE) Infections

For VRE intra‑abdominal infections, use tigecycline 100 mg IV loading dose followed by 50 mg IV every 12 h. 17, 18, 19
For uncomplicated VRE urinary tract infections, preferred oral/IV options are fosfomycin 3 g single dose, nitrofurantoin 100 mg every 6 h, or high‑dose ampicillin (18–30 g/day IV divided doses). 17, 18, 19

High‑Dose Tigecycline: Efficacy, Indications, and Pharmacokinetic Limitations

Efficacy of High‑Dose Regimens

In severe infections, especially hospital‑acquired pneumonia, a high‑dose regimen (200 mg loading dose followed by 100 mg every 12 h) demonstrated numerically superior efficacy compared with the standard 50 mg every 12 h schedule. 21

Specific Indications for High‑Dose Tigecycline

Multidrug‑resistant Acinetobacter baumannii (MIC ≤ 1 mg/L), particularly pulmonary infections: the recommended regimen is a 200 mg loading dose then 100 mg every 12 h, administered in combination with another active antimicrobial. 21
Hospital‑acquired pneumonia (HAP/VAP): standard dosing yielded a cure rate of 47.9 % versus 70.1 % for imipenem; the high‑dose regimen achieved an 85 % cure rate, markedly higher than the 69.6 % cure observed with standard dosing. 21
Nontuberculous mycobacterial (NTM) infections: guideline recommendations advise 25–50 mg once daily (or twice daily) to minimise drug‑related adverse events, with most experts preferring once‑daily administration. 22

Pharmacokinetic Limitations of Standard Dosing

With the FDA‑approved 50 mg every 12 h regimen, tigecycline attains a maximum serum concentration (Cmax) of only ≈ 0.87 mg/L, which is insufficient for effective treatment of bloodstream infections. 21
Clinical series have shown poor outcomes when standard‑dose tigecycline is used for A. baumannii bacteremia, supporting the recommendation to avoid tigecycline for bacteremia/bloodstream infections. 21

Tigecycline Dosing and Indications for Resistant Bacterial Infections

Hepatic Impairment

In patients with severe hepatic impairment (Child‑Pugh C), the maintenance dose should be reduced to 25 mg IV every 12 hours after the standard 100 mg loading dose; clinicians should use tigecycline judiciously in this population because clearance is roughly halved. 23

Acinetobacter baumannii (CRAB)

Tigecycline efficacy against carbapenem‑resistant Acinetobacter baumannii is MIC‑dependent: it is comparable to polymyxin when the MIC is ≤ 2 mg/L but is inferior when the MIC exceeds 2 mg/L; therefore, MIC testing must be performed before use. 23

Vancomycin‑Resistant Enterococcus (VRE) Bacteremia

For VRE bloodstream infections, tigecycline should be avoided; preferred agents are linezolid 600 mg IV every 12 hours or daptomycin 8–12 mg/kg IV daily. 24

Carbapenem‑Resistant Enterobacterales (CRE)

Bloodstream Infections

Recommended regimen: 100 mg tigecycline IV loading dose, then 50 mg IV every 12 hours, combined with colistin or meropenem administered as an extended infusion, for a total duration of 7–14 days. Preferred alternative agents include ceftazidime‑avibactam, meropenem‑vaborbactam, or imipenem‑relebactam. 24

Complicated Intra‑Abdominal Infections

Recommended regimen: 100 mg tigecycline IV loading dose, then 50 mg IV every 12 hours for 5–7 days. In clinically unstable patients, add a polymyxin or meropenem to the regimen. 24